Specifically, the treatment of myeloma cells with bortezomib induced cross-regulation between TLR4 and the HO-1/CO signaling pathway, which subsequently increased the unfolded protein response and protected the function of mitochondria, leading to decreased apoptosis resulting from the cytotoxic effects of bortezomib [196]. The gene discussed is HMOX1; the disease is plasma cell myeloma.